Abstract 240P
Background
The efficacy of first-line combination immuno-oncology therapy (IO) with ipilimumab plus nivolumab in metastatic renal cell carcinoma was demonstrated in the international phase III randomized CheckMate-214 trial. We also realized that the prognosis of Inter/Poor risk metastatic renal cancer could be extended in real clinical practice.
Methods
At Juntendo Univ. Hosp., Ipilimumab plus Nivolumab was used as first-line combination therapy for total 30 patients, including 27 patients with real-world Inter/Poor risk metastatic renal cell carcinoma from Jan/2019 to Aug/2023 and 3 patients enrolled in the international phase III study CheckMate-214. Efficacy in overall survival and safety, mainly immune-related adverse events(irAE), were retrospectively analyzed.
Results
Median age was 63 years (27-79), 37% (11/30) had prior nephrectomy. The most common metastatic lesions were lung (60%), bone (47%), and lymph node (37%). Three cases of hemodialysis were also included. The IMDC risk classification was Favor: Inter: Poor =2: 18: 10 cases. Total 80% (24/30) of cases were able to complete 4 cycles of ipilimumab. The average duration of IO treatment was 15.8 months (2-63). And the average duration of response was 27.3 months (2-92). During the mean follow-up period of 26.5 months (2-94), 6 cases died from cancer and 2 deaths from other causes. Among the cancer death cases, 4 of 6 cases were non-clear cell RCC. Deferred cytoreductive nephrectomy (DCN) could be performed in 2 cases in which metastatic lesions were controlled by IO-combo therapy. DCN was also performed in one patient withdrawn due to irAE, and surgical complete response (CR) was obtained. A total of 23% (7/30) had irAEs that forced IO administration to be discontinued. For irAEs of endocrine disorders, such as adrenal insufficiency and diabetes type 1, IO treatment could be continued with appropriate hormone replacement.
Conclusions
IO-Combo treatment for metastatic RCC was performed effectively and safely in Japanese patients. Surgical CR may be achieved with DCN after IO combination therapy even in poor-risk patients, but there is a possibility that Ipilimumab plus Nivolumab treatment has weak efficacy for non-clear cell RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract